Home › FDA Approves Mercks KEYTRUDA (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy
 

Keywords :   


FDA Approves Mercks KEYTRUDA (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy

2016-08-06 01:30:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA (pembrolizumab), the companys anti-PD-1 (programmed death receptor-1) therapy, at a fixed dose of 200 mg every three weeks, for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orInvestor:Teri Loxam, 908-740-1898orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: or head cell disease

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.05Trust in Paint Brand and Retailer Now Major Indicator of Customer Satisfaction, J.D. Power Finds
07.05Interpon Launches Structura Powder Coating Collection in North America
07.05Henry Rose Hires Industry Executive Laure de Metz as New CEO
07.05TikTok sues to block US law that could ban app
07.05Labels Unlimited adds second Durst Tau RSC E digital press
07.05Visitor Registration Open for Coatings for Africa
07.05Sofia Coppola Showcases Augustinus Bader Lip Balm at Met Gala
07.05OQ Chemicals Resumes Operations in German Plants
More »